Lyophilisation and why the cake looks the way it does

Posting this under the heading it deserves: Lyophilisation and why the cake looks the way it does Everything below is what sits behind that.

I would like to understand what this number means before I repeat it anywhere.

A Medutest report on a retatrutide lot gives 98.9% purity. The supplier certificate for the same lot states 98.5%. Both documents name a reversed-phase method; neither states the same gradient.

My question is not "who is right". It is: given that those two figures were produced by different methods, what is the largest difference I should expect from method alone, and at what point does a gap stop being explainable that way?

Worth separating two things that the opening post runs together.

Excipients and their purposes: mannitol, sucrose, or other sugars in lyophilised formulations protect the peptide during drying and storage. They are not impurities; they are functional components.

This follows post #2 rather than contradicting it.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

Preservatives: solutions for multi-dose vials contain preservatives (benzyl alcohol, phenol, or others) to inhibit microbial growth after the vial has been entered. Single-use vials do not need preservatives.

post #4 answers the question as asked. The question underneath it is different.

Fill volume and headspace: the amount of solution in a vial and the air above it affect how much the solution is exposed to oxygen during storage. Less headspace means less oxygen exposure.

On post #2 — agreed on the reasoning, with one qualification.

Container closure: the vial material, rubber closure, and sealing all affect permeability to water and oxygen. Glass is less permeable than plastic. Rubber quality matters.

Antioxidants: compounds that prevent oxidation (which damages peptides) are sometimes included. Methionine oxidation is a common degradation pathway and antioxidants help prevent it.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

Amino acid residues and formulation: the specific sequence and composition of a peptide affects what formulation conditions it tolerates. Sequences high in methionine need more antioxidant protection. Sequences prone to aggregation need different pH or additive protection.

I read post #9 twice before replying, because I had assumed the opposite.

Emulsification and suspensions: some formulations are emulsions or suspensions rather than solutions. Semaglutide formulations are solutions; some other compounds are suspensions. The physical form affects stability and administration.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

Buffers and pH: the pH of a solution is buffered to maintain stability. The buffer system (phosphate, Tris, or other) is chosen to keep the solution at the pH where the peptide is most stable.

post #13 is right about the mechanism and I think understates the practical bit.

Isotonicity: an isotonic solution has the same osmotic pressure as blood. Non-isotonic solutions can cause discomfort on injection. Injectable peptide solutions are formulated to be isotonic.